Posted by Michael Wonder on 21 Feb 2025
FDA approves first treatment for cerebrotendinous xanthomatosis, a rare lipid storage disease
21 February 2025 - Today, the US FDA approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis in adults.
Ctexli is the first FDA approved drug to treat cerebrotendinous xanthomatosis, a very rare lipid storage disease.
